UroGen Total Stockholder Equity vs Cash And Short Term Investments Analysis

URGN Stock

USD 10.77 0.23 2.18%

UroGen Pharma financial indicator trend analysis is much more than just breaking down UroGen Pharma prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether UroGen Pharma is a good investment. Please check the relationship between UroGen Pharma Total Stockholder Equity and its Cash And Short Term Investments accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.

Total Stockholder Equity vs Cash And Short Term Investments

Total Stockholder Equity vs Cash And Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of UroGen Pharma Total Stockholder Equity account and Cash And Short Term Investments. At this time, the significance of the direction appears to have almost no relationship.

The correlation between UroGen Pharma's Total Stockholder Equity and Cash And Short Term Investments is 0.1. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of UroGen Pharma, assuming nothing else is changed. The correlation between historical values of UroGen Pharma's Total Stockholder Equity and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of UroGen Pharma are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Total Stockholder Equity i.e., UroGen Pharma's Total Stockholder Equity and Cash And Short Term Investments go up and down completely randomly.

Correlation Coefficient

0.1

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of UroGen Pharma balance sheet. This account contains UroGen Pharma investments that will expire within one year. These investments include stocks and bonds that can be liquidated by UroGen Pharma fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Most indicators from UroGen Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into UroGen Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.At this time, UroGen Pharma's Selling General Administrative is very stable compared to the past year. As of the 17th of February 2025, Tax Provision is likely to grow to about 1.2 M, while Issuance Of Capital Stock is likely to drop about 41.2 M.

UroGen Pharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Long Term Debt	Common Stock Total Equity	Short Term Investments	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Property Plant And Equipment Gross
Total Assets		0.93	0.96	-0.03	-0.16	0.82	-0.08	-0.87	0.8	0.86	0.61	0.93	0.87	0.78	0.95	0.78	0.99	0.96	0.69	0.92	0.91	0.78	0.75	0.74	0.88	0.9
Other Current Liab	0.93		0.99	-0.31	-0.43	0.76	0.08	-0.96	0.68	0.85	0.39	0.82	0.87	0.92	0.99	0.9	0.95	0.97	0.57	0.83	0.86	0.55	0.64	0.87	0.9	0.93
Total Current Liabilities	0.96	0.99		-0.28	-0.39	0.75	0.03	-0.96	0.77	0.89	0.38	0.86	0.89	0.92	1.0	0.89	0.98	0.99	0.56	0.88	0.9	0.63	0.7	0.87	0.9	0.91
Total Stockholder Equity	-0.03	-0.31	-0.28		0.99	0.18	-0.78	0.45	-0.01	-0.06	0.5	0.1	-0.14	-0.61	-0.27	-0.65	-0.12	-0.23	0.53	0.04	-0.03	0.43	0.13	-0.7	-0.13	-0.17
Net Tangible Assets	-0.16	-0.43	-0.39	0.99		0.12	-0.76	0.53	-0.1	-0.19	0.43	0.0	-0.23	-0.69	-0.39	-0.75	-0.25	-0.35	0.45	-0.06	-0.12	0.35	0.06	-0.78	-0.21	-0.31
Property Plant And Equipment Net	0.82	0.76	0.75	0.18	0.12		-0.21	-0.73	0.6	0.63	0.68	0.84	0.8	0.59	0.78	0.49	0.78	0.73	0.9	0.78	0.87	0.72	0.74	0.44	0.9	0.64
Net Debt	-0.08	0.08	0.03	-0.78	-0.76	-0.21		-0.18	-0.27	-0.31	-0.14	-0.24	-0.11	0.34	0.04	0.43	-0.06	-0.01	-0.49	-0.26	-0.19	-0.51	-0.33	0.48	-0.08	0.02
Retained Earnings	-0.87	-0.96	-0.96	0.45	0.53	-0.73	-0.18		-0.71	-0.78	-0.27	-0.79	-0.88	-0.97	-0.96	-0.93	-0.9	-0.93	-0.45	-0.8	-0.87	-0.49	-0.64	-0.91	-0.92	-0.82
Accounts Payable	0.8	0.68	0.77	-0.01	-0.1	0.6	-0.27	-0.71		0.82	0.31	0.89	0.84	0.62	0.74	0.6	0.83	0.8	0.43	0.88	0.87	0.84	0.85	0.57	0.78	0.58
Cash	0.86	0.85	0.89	-0.06	-0.19	0.63	-0.31	-0.78	0.82		0.25	0.83	0.82	0.71	0.87	0.7	0.9	0.9	0.55	0.87	0.83	0.72	0.73	0.66	0.77	0.82
Non Current Assets Total	0.61	0.39	0.38	0.5	0.43	0.68	-0.14	-0.27	0.31	0.25		0.6	0.42	0.12	0.41	0.14	0.49	0.38	0.77	0.43	0.47	0.64	0.39	0.1	0.47	0.48
Cash And Short Term Investments	0.93	0.82	0.86	0.1	0.0	0.84	-0.24	-0.79	0.89	0.83	0.6		0.93	0.65	0.85	0.63	0.92	0.88	0.72	0.92	0.96	0.85	0.86	0.58	0.91	0.77
Common Stock Shares Outstanding	0.87	0.87	0.89	-0.14	-0.23	0.8	-0.11	-0.88	0.84	0.82	0.42	0.93		0.79	0.89	0.74	0.89	0.88	0.61	0.83	0.92	0.66	0.84	0.7	0.94	0.77
Other Current Assets	0.78	0.92	0.92	-0.61	-0.69	0.59	0.34	-0.97	0.62	0.71	0.12	0.65	0.79		0.92	0.97	0.84	0.89	0.28	0.71	0.76	0.33	0.53	0.97	0.81	0.76
Other Stockholder Equity	0.95	0.99	1.0	-0.27	-0.39	0.78	0.04	-0.96	0.74	0.87	0.41	0.85	0.89	0.92		0.89	0.97	0.98	0.59	0.87	0.9	0.61	0.69	0.86	0.92	0.91
Total Liab	0.78	0.9	0.89	-0.65	-0.75	0.49	0.43	-0.93	0.6	0.7	0.14	0.63	0.74	0.97	0.89		0.83	0.87	0.18	0.67	0.69	0.31	0.47	1.0	0.73	0.79
Total Current Assets	0.99	0.95	0.98	-0.12	-0.25	0.78	-0.06	-0.9	0.83	0.9	0.49	0.92	0.89	0.84	0.97	0.83		0.99	0.63	0.94	0.92	0.74	0.76	0.79	0.89	0.9
Common Stock	0.96	0.97	0.99	-0.23	-0.35	0.73	-0.01	-0.93	0.8	0.9	0.38	0.88	0.88	0.89	0.98	0.87	0.99		0.56	0.92	0.91	0.66	0.72	0.84	0.88	0.91
Property Plant Equipment	0.69	0.57	0.56	0.53	0.45	0.9	-0.49	-0.45	0.43	0.55	0.77	0.72	0.61	0.28	0.59	0.18	0.63	0.56		0.65	0.69	0.72	0.62	0.13	0.69	0.58
Long Term Debt	0.92	0.83	0.88	0.04	-0.06	0.78	-0.26	-0.8	0.88	0.87	0.43	0.92	0.83	0.71	0.87	0.67	0.94	0.92	0.65		0.95	0.83	0.84	0.62	0.86	0.73
Common Stock Total Equity	0.91	0.86	0.9	-0.03	-0.12	0.87	-0.19	-0.87	0.87	0.83	0.47	0.96	0.92	0.76	0.9	0.69	0.92	0.91	0.69	0.95		0.79	0.84	0.65	0.97	0.73
Short Term Investments	0.78	0.55	0.63	0.43	0.35	0.72	-0.51	-0.49	0.84	0.72	0.64	0.85	0.66	0.33	0.61	0.31	0.74	0.66	0.72	0.83	0.79		0.74	0.26	0.68	0.51
Long Term Debt Total	0.75	0.64	0.7	0.13	0.06	0.74	-0.33	-0.64	0.85	0.73	0.39	0.86	0.84	0.53	0.69	0.47	0.76	0.72	0.62	0.84	0.84	0.74		0.43	0.77	0.55
Non Current Liabilities Total	0.74	0.87	0.87	-0.7	-0.78	0.44	0.48	-0.91	0.57	0.66	0.1	0.58	0.7	0.97	0.86	1.0	0.79	0.84	0.13	0.62	0.65	0.26	0.43		0.7	0.76
Capital Surpluse	0.88	0.9	0.9	-0.13	-0.21	0.9	-0.08	-0.92	0.78	0.77	0.47	0.91	0.94	0.81	0.92	0.73	0.89	0.88	0.69	0.86	0.97	0.68	0.77	0.7		0.75
Property Plant And Equipment Gross	0.9	0.93	0.91	-0.17	-0.31	0.64	0.02	-0.82	0.58	0.82	0.48	0.77	0.77	0.76	0.91	0.79	0.9	0.91	0.58	0.73	0.73	0.51	0.55	0.76	0.75

Click cells to compare fundamentals

UroGen Pharma Account Relationship Matchups

UroGen Pharma fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	122.0M	119.7M	136.2M	178.3M	205.1M	215.3M
Other Current Liab	18.2M	16.6M	17.4M	24.7M	28.4M	29.8M
Total Current Liabilities	21.4M	22.4M	23.9M	31.2M	35.9M	37.7M
Total Stockholder Equity	96.4M	8.4M	(88.7M)	(65.2M)	(58.7M)	(55.8M)
Net Tangible Assets	180.3M	96.4M	8.4M	(89.4M)	(102.8M)	(97.6M)
Property Plant And Equipment Net	4.2M	3.1M	3.7M	2.4M	2.7M	2.1M
Net Debt	(102.4M)	(44.0M)	43.7M	4.4M	4.0M	4.2M
Retained Earnings	(356.5M)	(467.3M)	(577.1M)	(679.3M)	(611.4M)	(580.8M)
Accounts Payable	3.3M	5.8M	5.5M	6.5M	7.5M	4.3M
Cash	103.9M	44.4M	55.4M	95.0M	109.3M	114.7M
Non Current Assets Total	6.4M	5.4M	6.7M	9.1M	10.5M	8.5M
Cash And Short Term Investments	103.9M	89.8M	100.0M	137.0M	157.5M	79.8M
Common Stock Shares Outstanding	21.8M	22.3M	22.8M	28.8M	33.2M	17.0M
Liabilities And Stockholders Equity	122.0M	119.7M	136.2M	178.3M	205.1M	215.3M
Other Current Assets	4.6M	8.7M	11.9M	11.1M	12.8M	13.4M
Other Stockholder Equity	452.5M	475.7M	487.8M	614.0M	706.1M	741.4M
Total Liab	25.7M	111.3M	225.0M	243.5M	280.1M	294.1M
Total Current Assets	115.6M	114.4M	128.9M	169.2M	194.6M	204.3M
Accumulated Other Comprehensive Income	271K	(25K)	(107K)	12K	13.8K	14.5K
Common Stock	60K	61K	63K	89K	102.4K	107.5K
Property Plant Equipment	4.7M	4.2M	2.0M	1.3M	1.5M	1.7M
Common Stock Total Equity	57K	60K	61K	63K	72.5K	45.9K
Short Term Investments	49.2M	44.8M	44.6M	42.0M	48.3M	43.2M
Non Current Liabilities Total	4.2M	89.0M	201.1M	212.3M	244.2M	256.4M
Capital Surpluse	408.0M	452.5M	475.7M	487.8M	561.0M	307.7M
Property Plant And Equipment Gross	4.2M	2.0M	1.3M	6.3M	7.3M	7.6M
Non Currrent Assets Other	289K	1.5M	2.7M	2.3M	2.6M	2.7M
Other Assets	487K	289K	29.9K	620K	713K	367.9K
Net Invested Capital	96.4M	8.4M	8.2M	33.3M	30.0M	55.5M
Net Working Capital	94.2M	92.0M	105.0M	138.0M	158.7M	112.3M
Retained Earnings Total Equity	(228.0M)	(356.5M)	(467.3M)	(577.1M)	(519.4M)	(545.4M)
Capital Stock	60K	61K	63K	89K	102.4K	68.6K
Short Long Term Debt Total	1.5M	398K	99.1M	100.2M	115.2M	121.0M
Capital Lease Obligations	1.5M	398K	1.6M	844K	759.6K	1.1M
Long Term Investments	1.9M	675K	0.0	4.5M	4.1M	3.8M

When determining whether UroGen Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of UroGen Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Urogen Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Urogen Pharma Stock:

How To Invest In UroGen

Details

Is UroGen Stock a good investment?

Details

What is UroGen Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.

You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.02)

Revenue Per Share

2.389

Quarterly Revenue Growth

0.209

Return On Assets

(0.21)

Return On Equity

(14.81)

The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

UroGen Total Stockholder Equity vs Cash And Short Term Investments Analysis

Total Stockholder Equity vs Cash And Short Term Investments

Total Stockholder Equity vs Cash And Short Term Investments Correlation Analysis

Correlation Coefficient

Total Stockholder Equity

Cash And Short Term Investments

UroGen Pharma fundamental ratios Correlations

UroGen Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

UroGen Pharma fundamental ratios Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Stockholder Equity	+ 1.0	Total Current Liabilities
Non Current Liabilities Total	+ 1.0	Total Liab
Total Current Assets	+ 0.99	Total Assets
Total Current Liabilities	+ 0.99	Other Current Liab
Other Stockholder Equity	+ 0.99	Other Current Liab
Common Stock	+ 0.99	Total Current Liabilities

Other Current Assets	- 0.97	Retained Earnings
Other Stockholder Equity	- 0.96	Retained Earnings
Retained Earnings	- 0.96	Total Current Liabilities
Retained Earnings	- 0.96	Other Current Liab
Common Stock	- 0.93	Retained Earnings
Total Liab	- 0.93	Retained Earnings